Absence of BCAP in myeloid cells abrogates M2 macrophage differentiation and promotes anti-tumor immunity

髓系细胞中BCAP的缺失会抑制M2巨噬细胞分化并促进抗肿瘤免疫。

阅读:13
作者:Kiana Kawarizadeh ,Charles N Vallez ,Sepideh Aliyazdi ,Kathrynne A Warrick ,Cierra Carafice ,Irene Saha ,Chandrashekhar Pasare

Abstract

B-cell adaptor for PI3K (BCAP) is a critical signaling adapter that links Toll-like receptors (TLRs) to the phosphatidylinositol 3-kinase (PI3K)-Akt pathway and negatively regulates TLR-induced inflammation. BCAP also facilitates transition of macrophages from an inflammatory (M1) to a reparatory (M2) state; however, whether BCAP functions downstream of receptors that directly drive M2 macrophage differentiation is not known. Here, we find that BCAP is essential for M2 differentiation in response to interleukin (IL)-4 and IL-33. BCAP-deficient macrophages displayed an impaired M2 gene program, marked by reduced expression of Arg1, Retnla, and Mgl2. Mechanistically, BCAP enables IL-4-driven PI3K-Akt activation by mediating interactions between p85 and Grb2 without impacting STAT6 function. Strikingly, loss of BCAP, either globally or in myeloid cells, leads to suppressed tumor growth and a shift in tumor-associated macrophages toward a pro-inflammatory state and less exhausted tumor-infiltrating CD8 T cells. These findings present BCAP as a promising therapeutic target for enhancing anti-tumor immunity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。